What podcasts say about Kura Oncology
Every statement, with the speaker, the exact quote and the moment it was said.
What experts have said about Kura Oncology
6 statements · 5 positive · 1 negative
A major Cura breakthrough would produce substantial stock gains.
“If Cara makes a big breakthrough, you're going to see huge gains.”
Open the episode · Mad Money w/ Jim Cramer 12/19/25Listen at 22:20
Cura Oncology could suffer severe losses after failed results or setbacks.
“If it doesn't or if there are setbacks, it will be eviscerated”
Open the episode · Mad Money w/ Jim Cramer 12/19/25Listen at 22:23
Broader leukemia approval could expand Cura’s drug market to $5–$10 billion.
“Right now, this drug is approved for one type of disease. That's a $350 to $500 million end market. But if it gets approved for every type of acute leukemia, well, then you know what? That's a $5 to $10 billion market.”
Open the episode · Mad Money w/ Jim Cramer 12/19/25Listen at 26:06
Broad leukemia approval could expand Cura’s market to $5–$10 billion.
“if it gets approved for every type of acute leukemia, well, then you know what? That's a $5 to $10 billion market.”
Open the episode · Mad Money w/ Jim Cramer 12/19/25Listen at 26:11
Cura’s $500 million market capitalization undervalues its cancer franchise.
“When you consider this market capitalization, it's just $500 million? Oh, come on, you're practically getting their whole cancer franchise for free.”
Open the episode · Mad Money w/ Jim Cramer 12/19/25Listen at 26:31
Cura is an attractive speculative vehicle for cancer-treatment exposure.
“if you want to speculate on cancer treatments, I think this could be a great way to go.”
Open the episode · Mad Money w/ Jim Cramer 12/19/25Listen at 26:46
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.